AccuStem Sciences, Inc. (ACUT)
OTCMKTS · Delayed Price · Currency is USD
0.2700
+0.0091 (3.49%)
At close: May 18, 2026
AccuStem Sciences Employees
AccuStem Sciences had 4 employees as of December 31, 2025. The number of employees increased by 2 or 100.00% compared to the previous year.
Employees
4
Change (1Y)
2
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$450,393
Market Cap
4.34M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 4 | 2 | 100.00% |
| Dec 31, 2024 | 2 | -1 | -33.33% |
| Dec 31, 2023 | 3 | -1 | -25.00% |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| LakeShore Biopharma | 573 |
| Adaptimmune Therapeutics | 506 |
| Orgenesis | 77 |
| Reviva Pharmaceuticals Holdings | 14 |
| Iterum Therapeutics | 9 |
| Mosaic ImmunoEngineering | 7 |
| Bioxytran | 2 |
AccuStem Sciences News
- 4 months ago - AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP) - GlobeNewsWire
- 8 months ago - AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning - GlobeNewsWire
- 8 months ago - AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th - GlobeNewsWire
- 1 year ago - AccuStem Sciences, Inc. Announces Chairman Purchase of Shares - GlobeNewsWire
- 1 year ago - AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening - GlobeNewsWire
- 1 year ago - AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan - GlobeNewsWire
- 1 year ago - AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States - GlobeNewsWire
- 1 year ago - AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test - GlobeNewsWire